Physician profile
Sayed Aamir Raza
NPI 1699785188
$737.50
in general payments reported to CMS, 2019-2025
11 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.76 · 2022: $110 · 2023: $280 · 2024: $227 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $121.86 | 2023 | Abilify Maintena |
| Indivior INC. | $95.19 | 2022-2023 | Perseris |
| Alkermes, INC. | $93.77 | 2024 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $93.62 | 2023 | Uzedy |
| Tersera Therapeutics LLC | $87.37 | 2025 | Xermelo |
| Bioxcel Therapeutics, INC. | $87.15 | 2024 | Igalmi |
| Vanda Pharmaceuticals INC. | $79.24 | 2022-2023 | Hetlioz, Fanapt |
| Medtronic, INC. | $28.52 | 2024 | Turbohawk |
| Sobi, INC | $19.47 | 2025 | |
| Astellas Pharma US INC | $17.55 | 2024 | Xospata |
| Biogen, INC. | $13.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.